Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs, the impact of buoyant interest rates on consumer spending and even elevated commodity prices. The ...
After losing its leading position in obesity, changing its CEO and triggering a major company reorganization, the pressure is ...
Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs. Read more at ...
Lilly moved first. In January 2024, it launched LillyDirect, linking patients with telehealth providers and home delivery for its diabetes and weight-management portfolio. Pfizer followed in August ...
Shifting drinking patterns and rising health concerns have hit earnings, compounded by US tariffs, the impact of buoyant ...
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of ...
Federal layoffs and government shutdown concerns are compounding worker anxieties about employment stability across public ...
‘We were sitting down for a drink, and a guy came up to us and asked if it was a bachelorette and what we were doing. He told ...
Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and ...
Wearing a sage-coloured gown and clutching a bouquet of white roses and eucalyptus, Sophie Hinchliffe gazed adoringly at the ...
Opinion
1dOpinion
GLP-1s may not be a solution for our obesity crisis. But limiting access to these weight-loss medications is not the answer.
As health insurance companies pull back on their coverage, R.I. needs to look for ways to buy in bulk and adopt a new health strategy, write doctors at the Rhode Island Public Health Institute.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback